

Synthesis and Antimicrobial Properties of New 4-(Alkylidene/arylidene)-amino-5-(2-furanyl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones and 6-Aryl-3-(2-furanyl)-7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazines

Nedime Ergenç^{a)*}, Nuray Ulusoy^{a)}, Gültaze Çapan^{a)}, Gülten Ötük Sanis^{b)}, and Muammer Kiraz^{c)}

^{a)} Department of Pharmaceutical Chemistry, Faculty of Pharmacy, ^{b)} Department of Microbiology, Faculty of Pharmacy, ^{c)} Department of Microbiology, Istanbul Faculty of Medicine, University of Istanbul, 34390 Istanbul, Turkey

Key Words: 1,2,4-triazoles; hydrazones; 7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazines; geometrical isomerism; antimicrobial activity

Summary

A series of 4-(alkylidene/arylidene)amino-5-(2-furanyl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones (2) and 6-aryl-3-(2-furanyl)-7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazines (3) were synthesized. The configuration of **2g** was assigned on the basis of ¹H-NMR data. Of the new derivatives tested, only **2b**, **2g**, and **4f** were found to be active against *Staphylococcus aureus* and/or *Staphylococcus epidermidis* (MIC 125–1.95 µg/ml), whereas all exhibited varying degrees of antifungal activity (MIC 25–0.8 µg/ml).


Introduction

The prevalence of resistant infections in spite of existing useful antimicrobial agents decreases the chemotherapeutic and chemopreventive alternatives and stimulates the search for new compounds. The 1,2,4-triazole nucleus and N-bridged heterocycles derived from it have recently been incorporated into a variety of compounds with antibacterial^[1], antifungal^[2] and antiparasitic^[3] properties. As part of a synthetic effort directed toward the synthesis of antimicrobial agents^[4], 4-amino-5-(2-furanyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione (**1**)^[5], a versatile substrate for mono- and difunctional electrophiles by virtue of its vicinal amino and thione/thiole groups, has been condensed with aldehydes and ω -bromoacetophenones to afford 4-(alkylidene/arylidene)amino-5-(2-furanyl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones (**2a-g**) and 6-aryl-3-(2-furanyl)-7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazines (**4a-f**), respectively.

Results and Discussion

Chemistry

The key intermediate **1** was prepared from furan-2-carbohydrazide following the method of Reid and Heindel^[6]. Condensation of **1** with appropriate aldehydes in ethanolic medium furnished **2a-g** in good yields (Scheme 1 and Table 1). **2a-g** are capable of existing in thiole or thione forms either as the *E* or *Z* isomers. The low field NH (δ 14.1 ppm)^[7]



Scheme 1

and N=CH resonances (δ 9.84–10.01 ppm)^[1] observed in the ¹H-NMR spectra indicated the presence of the thione form and only one isomer, the *E* isomer. The paramagnetic shift observed for the N=CH proton was attributed to the anisotropy of the thiocarbonyl group which could be effective only in the *E* form. To confirm this assignment **2a** was reacted with C₆H₅CH₂Cl in the presence of K₂CO₃ to yield the thioether derivative **3**. As expected, the ¹H-NMR spectrum of **3** displayed the N=CH proton at δ 8.73 ppm^[8]. **2g** existed as the *E* configured species about the ethylenic bond as reflected by the 16 Hz coupling constant^[9] observed in the ¹H-NMR

Table 1. Formula, % yields and melting points of **2–4**.

| Comp. | R | Mp [°C] | Yield [%] | Formula ^{a)} (Molecular mass) |
|-----------|---|------------|--------------|--|
| 2a | 4-CH ₃ C ₆ H ₄ | 224–225 | 76 | C ₁₄ H ₁₂ N ₄ OS (284.34) |
| 2b | 4-BrC ₆ H ₄ | 219–220 | 67 | C ₁₃ H ₉ BrN ₄ OS (349.21) |
| 2c | 2,5-(OH)BrC ₆ H ₃ | 218–219 | 95 | C ₁₃ H ₉ BrN ₄ O ₂ S (365.21) |
| 2d | 2,6-Cl ₂ C ₆ H ₃ | 234 | 70 | C ₁₃ H ₈ Cl ₂ N ₄ OS (339.19) |
| 2e | 4-COOH C ₆ H ₄ | 240–241 | 79 | C ₁₄ H ₁₀ N ₄ O ₃ S (314.32) |
| 2f | 2-NO ₂ C ₆ H ₄ | 233–234 | 90 | C ₁₃ H ₉ N ₅ O ₃ S (315.31) |
| 2g | 2-(5-nitro-2-furyl)- ethenyl | 219–220 | 87 | C ₁₃ H ₉ N ₅ O ₄ S (331.31) |
| 3 | 4-CH ₃ C ₆ H ₄ | 98–99 | 73 | C ₂₁ H ₁₈ N ₄ OS (374.12) |
| 4a | C ₆ H ₅ | 163–165 | 75 | C ₁₄ H ₁₀ N ₄ OS (282.32) |
| 4b | 4-CH ₃ C ₆ H ₄ | 185–186 | 89 | C ₁₅ H ₁₂ N ₄ OS (296.36) |
| 4c | 4-OCH ₃ C ₆ H ₄ | 172–173 | 96 | C ₁₅ H ₁₂ N ₄ O ₂ S (312.36) |
| 4d | 4-ClC ₆ H ₄ | 220–221 | 81 | C ₁₄ H ₉ ClN ₄ OS (316.76) |
| 4e | 4-BrC ₆ H ₄ | 234–235 | 88 | C ₁₄ H ₉ BrN ₄ OS (361.22) |
| 4f | 4-NO ₂ C ₆ H ₄ | >300 | 91 | C ₁₄ H ₉ N ₅ O ₃ S (327.32) |

^{a)} Satisfactory analyses were obtained.

spectrum. Since *s-trans* conformation (about the sp³ C–C bond) has been reported to be the more stable form^[10] the structure of **2g** is proposed as *s-trans*. The structures were quite stable under EI and provided abundant molecular ions. The major fragmentation pattern observed in the EIMS involved N–N bond cleavage at position 4- of the 1,2,4-triazole system furnishing C₆H₅N₃OS⁺ (*m/z* 167) and RC₇H₄N⁺ which subsequently led to fragments characteristic for the 1,2,4-triazole and aldehyde moieties^[11,12]. Additional spectral characteristics are presented in the experimental.

Reaction of **1** with substituted ω-bromoacetophenones in absolute ethanol yielded **4a–f** (Scheme 1 and Table 1). The literature method^[3] was slightly modified and the neutralization step was omitted since the products before and after neutralization were identical (TLC, m.p., IR). Absence of the N–H absorptions in both IR and ¹H-NMR spectra and observation of additional resonances assigned to the SCH₂ (δ 4.00–4.07 ppm) and to the aryl protons (δ 6.94–8.42 ppm) at the 6-position in the ¹H-NMR spectra confirmed cyclocondensation to **4a–f**^[13]. Further verification for ring closure was obtained from EIMS where the molecular ions were the base peaks. The major fragmentation route involved concomitant breaking of the N–N and C–C bonds of the 1,3,4-thiadiazine system, yielding fragments C₇H₅N₃OS⁺ (*m/z* 179) and RC₇H₄N⁺, which was consistent with the literature^[3]. Additional spectral details are presented in the experimental section.

Microbiology

2a–g and **4a–f** were evaluated for *in vitro* antimicrobial action against some bacteria (*Staphylococcus aureus* ATCC 6538, *Staphylococcus epidermidis* ATCC 12228, *Escherichia coli* ATCC 8739, *Klebsiella pneumoniae* UC 57, *Shigella flexneri*, *Pseudomonas aeruginosa* ATCC 1539, *Proteus mirabilis* and *Salmonella typhi*) and fungi (*Trichophyton tonsurans* NCPF 245, *Trichophyton mentagrophytes* var. *erinacei* ATCC 375, *Trichophyton mentagrophytes*, *Microsporum gypseum* NCPF 580, *Microsporum canis*, *Microsporum audouinii*) using the microdilution method^[14,15]. Mueller Hinton Broth, Yeast Nitrogen Base (YNB Difco) and Nutrient Broth media were used in the tests. The substances and the standards – nifuroxazole, miconazole and clotrimazole – were dissolved in DMSO to give serial dilutions of 250–0.49 or 234–0.49 µg/ml and 25–0.20 µg/ml for the antibacterial and antifungal activity tests, respectively. Only **2b**, **2g**, and **4f** showed antibacterial activity whereas all the compounds showed varying degrees of antifungal activity against the microorganisms used (Table 2). The correlation between structure and antifungal activity in these series was not straightforward, however, some trends could be observed. As can be seen in Table 2 compounds **2** were more active than compounds **4**. Among **2**, the 4-substituted derivatives were more active than other entries with substituents at the 2- and/or 5-positions where there was no preference for the electronic nature of the substituent. The most active compound was the 4-Br substituted derivative **2b** followed by the 4-CH₃ and 4-COOH substituted derivatives **2a** and **2e**. Potency was insensitive to the electronic nature of the substituent on the phenyl ring in **4** also, where the most active

Table 2. Antibacterial and antifungal activity of **2** and **4** (MIC $\mu\text{g}/\text{ml}$).

| Comp. | Microorganism | | | | | | | |
|--------------|---------------|------|------|------|------|------|------|------|
| | A | B | C | D | E | F | G | H |
| 2a | | | 6 | 12.5 | 6 | 6 | 12.5 | 6 |
| 2b | 117 | 125 | 0.8 | 12.5 | 6.2 | 12.5 | 6.2 | 3 |
| 2c | | | 12.5 | 12.5 | 12.5 | 12.5 | 25 | 6.2 |
| 2d | | | 25 | 25 | 25 | 25 | 25 | 25 |
| 2e | | | 3 | 12.5 | 12.5 | 12.5 | 0.8 | 12.5 |
| 2f | | | 25 | >25 | 25 | 25 | >25 | 25 |
| 2g | 3.66 | 1.95 | 12.5 | 12.5 | 12.5 | 12.5 | 25 | 6.2 |
| 4a | | | 3 | 25 | 25 | 25 | 25 | 25 |
| 4b | | | 25 | >25 | 12.5 | 25 | 25 | 25 |
| 4c | | | >25 | >25 | 6.2 | 6.2 | >25 | >25 |
| 4d | | | 25 | >25 | >25 | 25 | >25 | >25 |
| 4e | | | 25 | >25 | 25 | 25 | 25 | 25 |
| 4f | | 7.81 | 25 | >25 | 6.2 | 12.5 | >25 | 25 |
| Miconazole | | | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| Clotrimazole | | | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
| Nifuroxazide | 0.97 | 0.97 | | | | | | |

A = *S. aureus* ATCC 6538, B = *S. epidermidis* ATCC 12228, C = *T. tonsurans* NCPF 245, D = *T. mentagrophytes* var. *erinacei* ATCC 375, E = *T. mentagrophytes*, F = *M. gypseum* NCPF 580, G = *M. canis*, H = *M. audouinii*

derivative was the unsubstituted compound **4a** followed by the 4-CH₃ and 4-NO₂ substituted entries **4b** and **4f**.

Experimental

M.p.'s: Büchi (Tottoli) melting point apparatus, uncorrected. – UV spectra: Shimadzu UV 2100S. – IR spectra: Perkin Elmer 1600 FT-IR (KBr). – ¹H-NMR spectra: Bruker AC 200(200 MHz) (TMS/CDCl₃ or ([D₆]DMSO). – EIMS: Pennsylvania State University (USA) or VG Zab Spec (70 eV) – TLC: precoated plates 60 F₂₅₄ (Merck Art. 5735) (CHCl₃:C₂H₅COCH₃, 1:4 or CH₃COCH₃:C₆H₆, 3:7). – Elemental analysis: Carlo Erba 1106.

4-(Alkylidene/arylidene)amino-5-(2-furanyl)-2,4-dihydro-3H-1,2,4-triazole-3-thiones (**2a-g**)

A mixture of **1** (0.01 mol) and an appropriate aldehyde (0.01 mol) in C₂H₅OH (150 ml) was refluxed for 3 h. The crude product that solidified on cooling was filtered, dried and recrystallized from C₂H₅OH.

2a UV (C₂H₅OH): λ max nm (log ε) = 287.8 (4.300), 254.4 (4.433), 215.4 (4.250). – IR (KBr): ν cm⁻¹ = 3085 (N–H), 1625, 1598, 1564, 1525, 1503 (C=N, C=C). – ¹H-NMR ([D₆]DMSO): δ = 14.16 (s, 1H, NH), 9.84 (s, 1H, N=CH), 7.95 (s, 1H, furan H5), 7.85 (d, J = 8.4 Hz, 2H, ar.), 7.49 (d, J = 8.4 Hz, 2H, ar.), 7.10 (d, J ,_{3,4} = 3.4 Hz, 1H furan H3), 6.72 (dd, J ,_{3,4} = 3.4 Hz, J ,_{4,5} = 1.5 Hz, 1H, furan H4), 2.49 (s, 3H, CH₃). – MS (70 eV): m/z (%) = 284 (100) [M⁺], 256(6) [M⁺ – N₂], 252(2) [M⁺ – S], 246 (3), 193 (6), 167 (64), 151(8), 138 (11), 117 (68), 108 (78), 102 (25), 94 (32), 93 (46), 79 (34), 63 (41).

2e UV (C₂H₅OH): λ max nm (log ε) = 289.4 (4.328), 254.6 (4.518). – IR (KBr): ν cm⁻¹ = 3354, 3100 (O–H/N–H), 1689 (C=O), 1630, 1612, 1564, 1558, 1529 (C=N, C=C). – ¹H-NMR ([D₆]DMSO): δ = 14.12 (s, 1H, NH), 13.20 (bs, 1H, OH), 10.01 (s, 1H, N=CH), 8.13 (d, J = 8.3 Hz, 2H, ar.), 8.06 (d, J = 8.3 Hz, 2H, ar.), 7.96 (s, 1H, furan H5), 7.15 (d, J ,_{3,4} = 3.4 Hz, 1H,

furan H3) 6.72 (dd, J ,_{3,4} = 3.4 Hz, J ,_{4,5} = 1.5 Hz, 1H, furan H4). – MS (70 eV): m/z (%) = 314(79) [M⁺], 282 (4) [M⁺ – S], 269 (4) [M⁺ – COOH], 245 (3), 221 (3), 203 (4), 193 (3), 192 (3), 170 (4), 167 (100), 147 (6), 130 (10), 108 (38), 102 (6), 94 (17), 93 (10), 39 (22).

3-(Benzylthio)-5-(2-furanyl)-4-(4-methylbenzylidene)amino-4H-1,2,4-triazole (**3**)

A mixture of **2a** (0.005 mol), C₆H₅CH₂Cl (0.005 mol) and K₂CO₃ (0.01 mol) in CH₃COCH₃ (20 ml), was refluxed for 3 h. Excess of solvent was distilled off to leave a viscous oil which solidified on trituration with petroleum ether. The solid thus obtained was recrystallized from C₂H₅OH to afford **3**.

3 UV (C₂H₅OH): λ max nm (log ε) = 267.5 (4.527). – IR (KBr): ν cm⁻¹ = 1599, 1562, 1514, 1495 (C=N, C=C). – ¹H-NMR ([D₆]DMSO): δ = 8.73 (s, 1H, N=CH), 7.87 (s, 1H, furan H5), 7.81 (d, J = 8.0 Hz, 2H, ar.), 7.39 (d, J = 8.0 Hz, 2H, ar.), 7.33–7.25 (m, 5H, ar.), 6.92 (d, J ,_{3,4} = 3.2 Hz, 1H, furan H3), 6.66 (dd, J ,_{3,4} = 3.2 Hz, J ,_{4,5} = 1.5 Hz, 1H, furan H4), 4.41 (s, 2H, SCH₂), 2.40 (s, 3H, CH₃).

6-Aryl-3-(2-furanyl)-7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazines (**4a-f**)

To a solution of **1** (0.01 mol) in absolute C₂H₅OH was added an appropriate ω-bromoacetophenone (0.01 mol). The mixture was refluxed for 5 h. The solid obtained during reflux or on cooling was filtered, dried and recrystallized from C₂H₅OH.

4e UV (C₂H₅OH): λ max nm (log ε) = 302.2 (4.337), 261.4 (4.414). – IR (KBr): ν cm⁻¹ = 1621, 1584, 1557, 1515, 1490 (C=N, C=C). – ¹H-NMR (CDCl₃): δ = 7.81 (d, J = 8.7 Hz, 2H, ar.), 7.69 (d, J = 8.7 Hz, 2H, ar.), 7.65 (s, 1H, furan H5), 7.16 (d, J ,_{3,4} = 3.3 Hz, 1H, furan H3), 6.58 (dd, J ,_{3,4} = 3.3 Hz, J ,_{4,5} = 1.5 Hz, 1H, furan H4), 4.00 (s, 2H, SCH₂). – MS (70 eV): m/z (%) = 360, 362 (100, 98) [M⁺, (M+2)⁺], 281 (5) [M⁺ – Br], 253(6), 225, 227 (7) (only ⁷⁹Br is given), 208, 210 (7), 195, 197 (49), 188 (10), 181, 183

(62), 179 (75), 160 (13), 155, 157 (32), 151 (34), 137 (21), 121 (62), 116 (10), 109 (65), 102 (89), 93 (78), 90 (5), 89 (17), 83 (27), 76 (60), 64 (32).

4f UV (C₂H₅OH): λ_{max} nm (log ε) = 305.4 (4.540), 266.1 (4.605).– IR(KBr): ν cm⁻¹ = 1618, 1607, 1598, 1523, 1514 (C=C, C=N, NO₂), 1346 (NO₂).– ¹H-NMR(CDCl₃): δ = 8.42 (d, J = 8.8 Hz, 2H, ar.), 8.12 (d, J = 8.8 Hz, 2H, ar.), 7.68 (s, 1H, furan H5), 7.16 (d, J_{3,4} = 3.4 Hz, 1H furan H3), 6.61 (s (distorted singlet), 1H, furan H4), 4.07 (s, 2H, SCH₂).– MS (70 eV): *m/z* (%) = 327 (100) [M⁺], 297 (14) [M⁺-NO], 281 (8) [M⁺-NO₂], 179 (25), 162 (18), 160 (5), 151 (10), 148 (50), 137 (18), 121 (44), 119 (22), 118 (19), 109 (34), 102 (37), 93 (55), 90 (26), 89 (26), 83 (8), 76 (33), 64 (25), 58 (66).

References

- [1] B.S. Holla, B. Kalluraya, *Indian J. Chem.* **1988**, *27B*, 683–685.
- [2] A.R. Prasad, T. Ramalingam, A.B. Rao, P.W. Diwan, P.B. Sattur, *Eur. J. Med. Chem.* **1989**, *24*, 199–201.
- [3] M.A. El-Dawy, A.M.M.E. Omar, AbM. Ismail, A.A.B. Hazzaa, *J.Pharm.Sci.* **1983**, *72*, 45–50.
- [4] N. Ergenç, G. Çapan, G. Ötük, *Pharmazie* **1993**, *48*, 780–782.
- [5] N. Hou, L.J. Xu, Yaxue Xuebao, 1992, *27*, 738–742; *Chem. Abstr.* **1993**, *118*, 124452y.
- [6] J.R. Reid, N.D. Heindel, *J. Heterocycl. Chem.* **1976**, *13*, 925–926.
- [7] F. Malbec, R. Milcent, G. Barbier, *ibid.* **1984**, *21*, 1689–1697.
- [8] N. Cesur, Z. Cesur, N. Ergenç, M. Uzun, M. Kiraz, Ö. Kasimoglu, D. Kaya, *Arch. Pharm. (Weinheim)* **1994**, *327*, 271–272.
- [9] J.R. Dimmock, W.G. Taylor, *J. Pharm. Sci.* **1974**, *63*, 69–74.
- [10] I.L. Finar, *Organic Chemistry*, 6th ed., Longman Singapore Publishers (Pte) Ltd. **1986**, p.130.
- [11] A.J. Blackmann, J.H. Bowie, *Aust. J. Chem.* **1972**, *25*, 335–343.
- [12] D.G.I. Kingston, H.P. Tannenbaum, G.B. Baker, J.R. Dimmrock, W.G. Taylor, *J. Chem. Soc.* **1970**, (C) 2574–2577.
- [13] M.A. Awad, A. Rahman, E.A. Bakite, *J. Chem. Technol. Biotechnol.* **1991**, *51*, 483–495.
- [14] R.N. Jones, A.L. Barry, T.L. Gavan, J.A. Washington, in *Manual of Clinical Microbiology*, 4th ed. (Ed.: A. Balows, W.J. Hausler, H.J. Shadomy), ASM, Washington DC, **1985**, pp 972–977.
- [15] T.C. Granade, W.M. Artis, *Antimicrob. Agent Chemother.* **1980**, *17*, 725–729.

Received: June 6, 1995 [N007]

© VCH Verlagsgesellschaft mbH, D-69451 Weinheim, 1996 – Printed in the Federal Republic of Germany

Anzeigeneleitung: H.-G. Schwarz, Thaddenstraße 14 a, D-69451 Weinheim, Telefon (06201) 606-567, Telefax (06201) 606-550 – VCH Verlagsgesellschaft mbH, Postfach 10161, D-69451 Weinheim.

Alle Rechte, insbesondere die der Übersetzung in fremde Sprachen, vorbehalten. Kein Teil dieser Zeitschrift darf ohne schriftliche Genehmigung des Verlages in irgendeiner Form – durch Fotokopie, Mikrofilm oder irgendein anderes Verfahren – reproduziert oder in eine von Maschinen, insbesondere von Datenverarbeitungsmaschinen verwendbare Sprache übertragen oder übersetzt werden.– All rights reserved (including those of translation into foreign languages). No part of this issue may be reproduced in any form – photoprint, microfilm, or any other means – nor transmitted or translated into a machine language without the permission in writing of the publishers.– Von einzelnen Beiträgen oder Teilen von ihnen dürfen nur einzelne Vervielfältigungsstücke für den persönlichen und sonstigen eigenen Gebrauch hergestellt werden. Die Weitergabe von Vervielfältigungen, gleichgültig zu welchem Zweck sie hergestellt werden, ist eine Urheberrechtsverletzung. Der Inhalt dieses Heftes wurde sorgfältig erarbeitet. Dennoch übernehmen Autoren, Herausgeber, Redaktion und Verlag für die Richtigkeit von Angaben, Hinweisen und Ratschlägen sowie für eventuelle Druckfehler keine Haftung. This journal was carefully produced in all its parts. Nevertheless, authors, editors and publishers do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.– Die Wiedergabe von Gerätschaftsnamen, Handelsnamen, Warenbezeichnungen u. dgl. in dieser Zeitschrift berechtigt nicht zu der Annahme, daß solche Namen ohne weiteres von jedermann benutzt werden dürfen. Es handelt sich häufig um gesetzlich eingetragene Warenzeichen, auch wenn sie in dieser Zeitschrift nicht als solche gekennzeichnet sind. Druck und Buchbinder: Druck Partner Rübelmann GmbH, D-69502 Hembsbach.– Unverlangt zur Rezension eingehende Bücher werden nicht zurückgesandt.

Valid for users in the USA: The appearance of the code at the bottom of the first page of an article in this journal (serial) indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients. This consent is given on the condition, however, that copier pay the stated per copy fee through the Copyright Clearance Center, Inc., for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective work, or for resale. For copying from back volumes of this journal see »Permissions to Photo-Copy: Publisher's Fee List« of the CCC.

Printed on chlorine- and acid-free paper/Gedruckt auf säurefreiem und chlorfrei gebleichtem Papier